In a “first of its kind” study, researchers at the University of Illinois, Chicago (UIC) have presented information suggesting a new potential direct link between herpes simplex virus type 1 (HSV-1) and neurodegenerative diseases, such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and glaucoma.
Researchers from The University of Texas MD Anderson Cancer Center say that grouping epidermal growth factor receptor (EGFR) mutations by structure and function can help to better match non-small cell lung cancer (NSCLC) patients to the most promising treatments.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Researchers found that blocking the activity of IL-6 at the blood-brain barrier increased the lifespan of fruit flies with cancer by 45% and also found that after 21 days, 75% of cancer-carrying lab mice treated with an IL-6 receptor blocker were alive, versus only 25% of untreated mice.
AbbVie is investing in eye gene therapy with a $370M upfront investment in Regenxbio's anti-VEGF gene therapy for treatment of retinal diseases. If various milestones are met then the U.S. biotech could earn up to $1.38B for the deal.
A specialized hydrogel can not only encapsulate and protect mRNA cancer vaccines from being broken down in the body, but can also target lymph nodes to activate immune cells, shows early stage research.
According to the study, one-in-six adults (17.3%) had at least one pathogenic genetic variant. When integrated with deep phenotyping that included imaging, blood test and other analytical methods, one-in-nine (11.9%) had genotype and phenotype associations, supporting the clinical diagnosis of a genetic disorder.
In this eBook, sponsored by Qiagen, we explore the opportunities and challenges of precision oncology and how molecular profiling is fundamental not only to inform on tumor diagnosis and prognosis, but also to drive therapeutic decisions in routine clinical care.
The VITAL Act would update federal lab standards under the Clinical Laboratory Improvement Amendments (CLIA), overseen by the U.S. Department of Health and Human Services (HHS)—through which LDTs would also be regulated under the Public Health Services Act, which gives HHS authority to respond to public health emergencies.
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech